arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Keros Therapeutics, Inc.

KROS
$11.66 ▼ -0.09 (-0.77%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
89
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Keros Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $230.9M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC -11.8% ↘
FCF / Share $-1.04 ↘
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-23.71M
— 0.0% —
Operating Margin Operating profit as % of sales
-107.9%
↑ +50.8% 84th
FCF / Share Free cash flow per share
$-1.04
↓ -466.3% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
92
Returns
92
Cash Quality ↑
73

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters